Announcements Trials
Browse Landscape

Phase

Phase 2 40Phase 1 19Phase 3 6Phase NA 3Phase 1/2 3Phase EARLY_PHASE1 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3NET 1Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 699Breast Neoplasms 630Neoplasms 582Leukemia, Myeloid, Acute 481Colorectal Neoplasms 456Multiple Myeloma 444Melanoma 426Prostatic Neoplasms 383Neoplasm Metastasis 373Pancreatic Neoplasms 363Recurrence 350Lymphoma 340Ovarian Neoplasms 325Lung Neoplasms 297Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 231Squamous Cell Carcinoma of Head and Neck 220Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 210Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Lymphoma, Mantle-Cell 167Triple Negative Breast Neoplasms 166

Interventions

iodophenyl metomidate 1TKM-080301 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Adrenocortical Carcinoma × Clear all
NCT04187404 2026-01-30

Spencer

Enterome

Phase 1/2 Terminated
70 enrolled 20 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT01262235 2019-01-16

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

Arbutus Biopharma Corporation

Phase 1/2 Completed
68 enrolled
EndocrineLymphoidNET

Carcinoid Tumor, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT00454103 2010-08-18

Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy

University of Wuerzburg

Phase 1/2 Completed
Endocrine

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡